FDA Finds 'Egregious' Manufacturing Violations at Nephron Pharmaceuticals Despite Years of Warnings
核心洞察
FDA inspectors found six major violations at Nephron Pharmaceuticals in August 2025, including lack of written procedures to prevent contamination and deficient environmental monitoring systems.
The company has failed to address recurring sterility issues despite receiving three FDA warning letters since 2020 and voluntarily recalling over 2 million drug doses in 2022.
Regulatory experts warn that repeated violations could lead to facility shutdown or consent decree, as the FDA has ongoing compliance activities with the South Carolina-based manufacturer.
Nephron Pharmaceuticals continues to face severe regulatory scrutiny from the Food and Drug Administration (搜索), with a recent inspection revealing what experts describe as "egregious" manufacturing violations that pose risks to patient safety. The South Carolina-based company, one of Lexington's largest employers, has failed to implement adequate sterility controls despite years of federal warnings and multiple product recalls.
Latest FDA Inspection Reveals Persistent Problems
FDA inspectors conducted 10 visits to Nephron's facility at 4500 12th St. Ext. in Lexington County between August 11 and August 22, 2025, documenting six critical observations that highlight the company's ongoing compliance failures. The violations include:
- Lack of established written procedures to prevent microbiological contamination of sterile drug products
- Deficient environmental monitoring systems in aseptic processing areas
- Failure to thoroughly review batch failures and specifications
- Inadequate production and process control procedures
- Deficient air filtration systems with high-efficiency particulate air filters
- Non-compliance with quality control unit responsibilities and procedures
At least four of these observations were previously identified in 2023 and 2024 inspection reports, indicating the company's persistent inability to address fundamental manufacturing deficiencies.
Alarming Safety Lapses Documented
The inspection revealed troubling examples of poor oversight and employee training. During the FDA's facility walkthrough in August, an alarm designed to alert staff to pressure changes had been sounding all morning. When questioned by regulators, an employee stated, "I don't do anything about alarms," according to the inspection report.
While the company's chief quality officer told inspectors that employees are trained to report and escalate alarms, no investigation was initiated until federal regulators inquired about the situation. This lack of management oversight created an "unacceptable risk of microbial ingress and contamination of sterile products," regulators noted, which "undermines sterility assurance and patient safety."
Technology System Failures Raise Additional Concerns
The inspection also uncovered significant issues with the company's electronic systems. Nephron's chief technology officer presented regulators with documentation showing approximately 18,022 logged "Access Violation" errors between April 2024 and March 2025. Neither company management nor technology vendors could explain the cause or impact of these system failures, raising questions about data integrity and manufacturing control.
Pattern of Non-Compliance Spans Years
Nephron's regulatory troubles extend back several years, with the company receiving three FDA warning letters since 2020. The most recent warning letters, issued in 2022, addressed manufacturing deficiencies and have not received close-out letters from the FDA, indicating ongoing compliance issues. An FDA spokesperson confirmed that "compliance activities for this firm are ongoing."
The company has issued 20 product recalls since 2012, according to FDA data. In 2022, Nephron voluntarily recalled more than 2 million drug doses over sterility concerns, yet many of the same issues identified during that period persist today.
Patient Safety Incidents Highlight Real-World Impact
The manufacturing problems have resulted in documented patient safety concerns. In February 2024, a parent filed a complaint with the FDA about their child's medication having a fruity odor. A month later, a hospital pharmacy director reported finding dark particles in a vial of medication typically used for asthma (搜索) treatment.
Following these complaints, Nephron failed to adequately review the unexplained discrepancies, according to a 2024 FDA report. This pattern of inadequate investigation has been a recurring theme in the company's regulatory history.
Cross-Contamination Issues Inadequately Addressed
A 2021 internal investigation conducted by Nephron identified cross-contamination (搜索) in at least three lots of drug products. However, the company did not "adequately identify the root cause or scope of potentially impacted lots in a timely manner," according to an October 2022 FDA warning letter.
The FDA criticized Nephron for delays in alerting regulators to issues with drugs already distributed to patients. "Only after the FDA's inspection did you perform additional investigation," the agency wrote. "Your lack of timely and comprehensive investigation failed to identify the extent of the cross-contamination (搜索) hazard to marketed drug products."
Expert Analysis Suggests Serious Regulatory Consequences
Carol Beirne, faculty director at Northwestern University's graduate program for regulatory compliance and former corporate quality manager at Abbott Laboratories, characterized the violations as particularly severe. "If you don't even have an operating procedure that employees have to follow, then you're really shooting in the dark. You're leaving it to happenstance," Beirne explained.
"If [a company] doesn't even have a procedure, I can tell you, that's very egregious," she added, noting that the FDA has the authority to shut down operations for repeated violations.
Beirne suggested that given the pattern of non-compliance, the FDA may move beyond warning letters to issue a consent decree, which would remove all or portions of the company's products from the market until more rigorous standards are met.
Company Response and Current Status
Of the 1,210 warning letters sent to South Carolina companies since 2020, only 11 were for drug products, with Nephron accounting for three of these instances. The company's CEO, Lou Kennedy, declined to answer questions when contacted by reporters, and it remains unclear which products, if any, the company is currently manufacturing.
The regulatory scrutiny comes as Nephron has listed its headquarters building for sale at $340 million, though the company has indicated it intends to lease back the facility once sold.
Despite the documented safety issues, Nephron's website continues to claim that its "team of experts ensure every substance that enters and exits our facility is safe for use," a statement that appears inconsistent with the FDA's findings regarding manufacturing controls and sterility assurance.